Colchicine Taper for Recurrent Pericarditis
Tapering colchicine is not mandatory for recurrent pericarditis, but if you choose to taper, reduce to 0.5 mg every other day (for patients <70 kg) or 0.5 mg once daily (for patients ≥70 kg) during the final weeks of a minimum 6-month treatment course. 1
Treatment Duration and Dosing
For recurrent pericarditis, colchicine should be continued for at least 6 months at weight-adjusted maintenance doses 1:
- ≥70 kg: 0.5 mg twice daily
- <70 kg: 0.5 mg once daily
This differs from acute (first episode) pericarditis, which requires only 3 months of therapy 1.
Tapering Strategy
The 2015 ESC Guidelines explicitly state that tapering colchicine is not necessary 1. However, if you opt to taper to potentially prevent symptom persistence or recurrence, the recommended approach is 1:
- Patients <70 kg: Reduce from 0.5 mg daily to 0.5 mg every other day in the final weeks
- Patients ≥70 kg: Reduce from 0.5 mg twice daily to 0.5 mg once daily in the final weeks
Critical Tapering Principles
Only attempt tapering when the patient is completely asymptomatic AND CRP is normalized 1. This is non-negotiable—any tapering with active inflammation risks immediate recurrence.
When tapering multiple medications simultaneously (colchicine plus NSAIDs/aspirin), stop one drug class at a time 1. The typical sequence is:
- Taper NSAIDs/aspirin first (over weeks to months, guided by symptoms and CRP)
- Then gradually discontinue colchicine last (over several months in difficult cases)
Recurrences can occur after discontinuation of each drug, so monitor closely during and after each taper 1.
Common Pitfalls to Avoid
Do not taper too quickly—the guidelines emphasize that longer tapering times should be considered for more difficult, resistant cases 1. In challenging recurrent pericarditis, colchicine may need to be continued beyond 6 months before any taper is attempted 1.
Avoid corticosteroids if possible—they are a major risk factor for recurrence (HR 2.27) 2 and create dependency. If steroids were used, their tapering must be extraordinarily slow, particularly below 15 mg/day prednisone, with decrements as small as 1.0-2.5 mg at intervals of 2-6 weeks 1.
Evidence Quality
The recommendation against mandatory tapering comes from Class I, Level A evidence showing colchicine reduces recurrence rates by approximately 50% in recurrent pericarditis 1, 3. The CORP trial demonstrated that 6 months of colchicine reduced recurrence from 55% to 24% (NNT=3) 3. The optional taper schedule is based on expert consensus (Class IIa, Level C) 1.
The key message: Most patients can simply stop colchicine after 6 months without tapering, provided they are asymptomatic with normal CRP. Tapering is an option, not a requirement, and should only be considered in select cases where you're concerned about rebound symptoms.